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Background/Purpose: Curettage followed by the application of iliac crest autograft was the traditional
treatment of hand enchondroma in Princess Margaret Hospital, Hong Kong.
Methods: We reviewed the results of 13 patients with hand enchondroma who were operated on in the
past 15 years (1999e2013). Eight patients (1999e2009) received iliac crest autograft after curettage,
whereas the other ﬁve patients (2009e2013) received artiﬁcial bone substitutes.
Results: Both groups of patients had good functional outcome and bone graft incorporation. There was
no recurrence. One patient in the autograft group had mild residual ﬁnger stiffness. One patient receiving
artiﬁcial bone substitutes had a gouty attack, early wound infection, and ﬁnger stiffness. The use of
artiﬁcial bone substitutes eliminated donor site morbidities, decreased operation time and, hospital stay.
They took a longer time for radiological incorporation than autograft, but it did not translate into adverse
clinical effects.
Conclusion: Artiﬁcial bone substitute is a good alternative to iliac crest autograft in the treatment of hand
enchondroma.
中 文 摘 要
在香港瑪嘉烈醫院, 治療手部內生軟骨瘤的傳統方法是刮除術和自體髂骨移植手術˳ 我們回顧了最近15年
(1999e2013)手部內生軟骨瘤的手術成效˳ 由1999至2009年, 8位病人接受了自體髂骨移植手術˳ 由2009至
2013年, 5位病人接受了人工合成骨移植手術˳ 兩組病人的手部功能回復理想, 移植骨成功癒合, 沒有復發的
病例˳ 一位接受自體髂骨移植手術的病人出現輕微手指僵硬的情況, 而另一位接受人工合成骨移植手術的病
人痛風症病發, 出現傷口感染和手指僵硬的情況˳ 使用人工合成骨可以避免髂骨傷口出現併發症, 減少手術和
住院時間˳ 人工合成骨需要較長的時間癒合, 但沒有帶來負面的臨床影響˳ 使用人工合成骨來治療手部內生
軟骨瘤是除了自體髂骨移植術以外的好選擇˳Introduction
Enchondromas are the most common benign bone tumours of
the hand (35e65%).1 They are islands of cartilage that persist in the
bone after endochondral ossiﬁcation. They can be seen at any age
and in any bone preformed in cartilage, but are the most commonly
found in the hands and feet. Enchondromas can be solitary or
multiple. Multiple enchondromatosis is found in Ollier's disease or
Maffucci's syndrome. Malignant transformation of a solitary
enchondroma into chondrosarcoma is rare, but the risk increases tocom.
ciation andHongKongCollegeofOrtho
-nc-nd/4.0/).25% in patients with Ollier's disease and 100% in those with Maf-
fucci's syndrome.2
Patients with enchondromas may present with local pain and
swelling, pathological fracture, or found incidentally on radio-
graphs. Classic radiographs show a well-deﬁned, central osteolytic
lesion in the metaphysealediaphyseal junction. There may be
expansion of the lesion with cortical thinning. They are most
commonly found in the proximal phalanx and distal metacarpal
bones of the hand.1
Treatment of enchondromas aims to provide a histological
diagnosis, maintain bony stability, prevent future fracture, and
eliminate symptoms if any. Curettage is the treatment of choice.paedic Surgeons. PublishedbyElsevier (Singapore) Pte Ltd. This is anopenaccess article under the
Figure 1. Exposure of the enchondroma after the cortical window was removed.
Figure 2. Curettage and evacuation of the enchondroma.
Figure 3. Application of an iliac crest autograft.
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small defects and goodbony stability because newbone formation is
induced at the curettage site.1,3 However, themost commonmethod
used is to augment the bone defect with bone graft. The standard
choice of bone graft was iliac crest autograft. In recent years,
the appearance of commercially-packed and readily available arti-
ﬁcial bone substitutes in themarket expanded our armamentarium.
Surgeons utilized different forms of artiﬁcial bone substitutes
(e.g., demineralized bone matrix,4 calcium phosphate cement,5 and
calciumsulfate pellets6). These bone substitutes providedgoodbone
incorporation and functional outcome, while eliminating potential
donor site complications associated with autograft.
Our hospital has started using artiﬁcial bone substitutes in the
treatment of enchondroma since 2009. Up to then, iliac crest
autograft was the standard source of bone graft. We reviewed the
results of patients treated with both modalities.
Patients and methods
Between 1999 and 2013, 13 patients received operations for
enchondroma of the hand. Seven patients were male and six were
female. The average age of patient was 40 years old (range, 4e67
years old). There were 14 enchondromas in total. One patient had
two enchondromas of the same hand (proximal phalanx of index
ﬁnger and little ﬁnger) which were operated by two teams of sur-
geons simultaneously. All were sporadic cases. No case of Ollier's
disease or Maffucci's syndrome was identiﬁed.
Six out of 13 patients (46%) presented with pain and swelling.
Six other patients (46%) presented with pathological fracture pre-
ceded by a trivial injury. All were treated with splintage until the
fracture healed before curettage and bone grafting were carried
out. The average duration of splintage was 16.5 weeks (range,
10e21 weeks). In one patient (8%), the diagnosis was an incidental
ﬁnding on a radiograph performed for another reason.
The most common site of occurrence of enchondroma was the
proximal phalanx (10 out of 14 enchondromas; 72%). Two
enchondromas occurred in the metacarpus (14%), one was found in
the distal phalanx (7%), and one in the middle phalanx (7%). The
order of location was similar to that quoted in the literature.
All 13 operations were performed under general anaesthesia.
Dorsal approach was adopted and the extensor tendon was
retracted. After adequate exposure, a cortical window was created
on the bone with a burr (Figure 1). Thorough curettage was per-
formed to evacuate the tumour (Figure 2), followed by water irri-
gation. The bone void was then ﬁlled with iliac crest autograft
(Figure 3) or artiﬁcial bone substitutes (Figures 4 and 5). The
cortical window was ﬁnally sutured back.
From 1999 to 2009, eight patients received autograft from the
iliac crest (7 out of 8 patients, including the patient with 2
enchondromas) or the distal radius metaphysis (1 patient, 4 years
old). In case of small enchondromas (2 out of 8 patients), a trephine
biopsy needle was used to obtain iliac crest or distal radius bone
graft. However, open harvest of iliac crest bone graft was done (6
out of 8 patients) for more sizeable lesions. The approximate vol-
ume of autograft used ranged from 0.5 mL to 4 mL. From 2009 to
2013, the other ﬁve patients received artiﬁcial bone substitutes,
three of them received demineralized bone matrix putty (DBX
Putty; Musculoskeletal Transplant Foundation and Synthes, Paoli,
PA, USA), one patient received Norian SRS Bone Void Filler (Syn-
thes), and one patient received ChronOS granules (Synthes).
All tumours were sent for histological examination and
conﬁrmed to be enchondroma. They were lobulated lesions con-
sisting of clusters of chondrocytes with small and round nuclei.
Myxoid changes, which can be seen in small bone chondroma, are
noted. No chondrosacroma was identiﬁed.
Figure 4. Application of Synthes DBX® putty.
Figure 5. Appilcation of Synthes ChronOS granules.
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logical fracture and those who received artiﬁcial bone substitutes
were put on splints for 4e6 weeks. More vigorous mobilization
exercise was started after the course of splintage.
All patients were followed up in the Orthopaedics & Trauma-
tology Specialist Out-patient Clinic of Princess Margaret Hospital to
determine results and complications. Patients were asked to com-
plete the Chinese QuickDASH questionnaire6 to determine their
functional outcome. It consisted of 11 questions regarding activities
of daily living and severity of symptoms, four optional questions
regarding abilities of work, four optional questions regarding sports
or music. A score of 1e5 was given to each question. Higher scores
represented increasing difﬁculty in performing certain activities.
The ﬁnal score was expressed in percentages, representing the
degree of functional disability. Serial X-rays were taken at the clinic
to determine the radiographic outcome.Figure 6. Images of preoperative and 3 months postiliac crest bond graft application:
bone graft is well incorporated.Results
The average operating time of the autograft group was 76 mi-
nutes (range, 47e155 minutes). The patient with two enchon-
dromas was counted as two separate procedures, and the operatingtime was 150 minutes and 155 minutes by two teams of surgeons
respectively. Curettage followed by the application of artiﬁcial bone
substitutes required an average of 52 minutes (range, 35e71
minutes).
The average duration of hospital stay for patients receiving iliac
crest or distal radius autograft was 2.75 days (range, 2e5 days). For
patients receiving artiﬁcial bone substitutes, the average duration
of hospitalization was 1.3 day (range, 0.5e2 days).
All patients attended regular follow-up in the Specialist Ortho-
paedic Clinic after the operation. The average duration of follow-up
of the autograft group was 25 months (range, 12e44 months).
Because artiﬁcial bone substitutes were introduced in our hospital
in more recent years (from 2009 to 2013), their follow-up duration
was relatively shorter than the autograft group, averaging 17
months (range, 4e42 months).
In general, patients treated with either modality had good
functional outcome. The average Chinese quickDASH score7 of the
autograft group was 2.4. All patients receiving autograft had no
residual pain over the digit, seven out of eight (87.5%) had full range
of motion, and all of them had full hand grip power. Only one of
them who presented with a pathological fracture of the proximal
phalanx initially and required an external ﬁxator (Synthes Mini
External Fixator) after bone grafting had a ﬂexion contracture of 10
of the proximal interphalangeal joint. None of them had wound
infection or residual pain of the iliac crest wound.
Patients receiving artiﬁcial bone substitutes had similar func-
tional results. Their average Chinese quickDASH score7 was 2.75. All
patients had no residual pain. Four out of ﬁve patients (80%) ach-
ieved full range of motion and full hand grip power. One of them
was complicated with gouty attack, early wound infection, and
stiffness of ﬁngers. He had known gouty arthritis and multiple
gouty tophi over the operated digit. There were preexisting oste-
oarthritic changes of the ﬁnger joints. The surgical trauma induced
a gouty attack which led to wound dehiscence, drainage of topha-
ceous material, and ﬁnally resulted in wound infection. The wound
eventually healed up at postop 8weeks with antibiotics and regular
dressing.
Figure 7. Synthes DBX® putty incorporated after 4 months.
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serial radiographs. Autografts were consolidated in a mean period
of 5 weeks (range, 4e6 weeks; Figure 6). Artiﬁcial bone substitutes
were incorporated in a mean duration of 19 weeks (range, 12e33
weeks; Figure 7). No case of nonunion or recurrence was detected
clinically or radiologically upon the latest follow-up.Discussion
The treatment of enchondroma with curettage and bone graft-
ing in our case series yielded a good result in general. Patient's
symptoms were eliminated, the bone grafts incorporated well, and
no recurrence occurred. However, there are some notable differ-
ences between the results of artiﬁcial bone substitutes and iliac
crest autograft.
The use of artiﬁcial bone substitutes decreased the operating
time and the duration of hospitalization when compared with
harvesting iliac crest bone graft. The average operating time was
cut down to 52 minutes from 76 minutes. The main reason was
obviously because there was no need to harvest the iliac crest bone
graft. There was also decreased blood loss. The risk of intra-
operative contamination of the iliac crest wound was eliminated.
Although our department performed all of the operations under
general anaesthesia, it could theoretically be done under digital
block with local anaesthesia if harvesting iliac crest bone graft was
not needed. The risks of general anaesthesia could then be
eliminated.
The average length of hospital stay of patients receiving artiﬁcial
bone graft was 1.3 days, which was shorter as compared with an
average of 2.75 days in patients receiving autograft. Within the
autograft group, the average length of hospital stay was slightly
shorter if the bone graft was harvested using a trephine biopsy
needle (2 days) rather than the open method (3 days). Patients
experienced postoperative iliac crest wound pain which delayed
their ambulation. Redivac drain was inserted into the iliac crest
wound in cases requiring open harvest of bone graft. Time needed
to return to ambulation and drainage of the iliac crest hematoma
contributed to the slightly prolonged hospital stay compared with
patients receiving artiﬁcial bone substitutes. If trephine biopsy
needle was used to obtain bone graft, the wound pain would bereduced and a surgical drain was not necessary. However, it might
be difﬁcult to obtain enough bone graft using a biopsy needle when
faced with a relatively sizeable lesion.
In our case series, autografts took an average of 5 weeks to
consolidate. This result is comparable to that quoted in the litera-
ture. Huseyin et al8 reported that consolidation of iliac crest auto-
graft took a mean of 38 days. Artiﬁcial bone substitutes, however,
take a longer and more variable time to incorporate. Our patients
require an average of 19 weeks for artiﬁcial bone graft incorpora-
tion. Jeffrey et al4 reported that demineralized bone matrix took 5
months for incorporation. Choy et al6 reported the mean time for
calcium sulfate pellet remodelling was 10 weeks. However, the
longer duration necessary for incorporation of artiﬁcial bone sub-
stitutes did not affect the ﬁnal functional outcome of our patient or
the healing rate of the bone graft. It implies that patient receiving
artiﬁcial bone substitutes may need a longer-term radiographic
follow-up.
Autograft is the standard treatment to ﬁll up the bone void after
curettage of enchondroma. It provides good osteogeneicity,
osteoinduction, and osteoconduction. The bone graft incorporation
is fast and reliable. However, autograft supply is limited. It may also
come with donor site morbidites, including wound pain, bleeding,
hematoma, infection, fracture, sensory loss, abdominal herniation,
and unsightly scar. Cosmetic problems over the iliac crest region
especially concern the female patients.
Huseyin et al8 investigated the application of allograft in treat-
ing hand enchondromas, and evaluated the long-term results of
both autograft and allograft application. They concluded that both
groups yielded good functional and radiographic results. Although
the allograft group took a longer time for consolidation (51 days)
compared with the autograft group (38 days), the clinical effect is
minimal. This result is expected as the morselized allografts only
have osteoconductive effect but do not have osteogenic or
osteoinductive properties. However, autografts contain all three
properties. Allografts also come with other disadvantages,
including immunological rejection and transmitting infective
diseases.
DBX® Demineralized Bone Matrix is one of the various kinds of
artiﬁcial bone substitutes used in our case series as well as reported
in the literature. It is an osteoinductive and osteoconductive ma-
terial composed of demineralized bone matrix from human donors
mixed with collagen carrier. The demineralized bone matrix is
produced by removingminerals from the cortical bone. It maintains
the trabecular scaffold of the original allograft and contains
osteoinductive growth factors. The bone morphogenic proteins
(BMPs) are the active components in demineralized bone matrix
which stimulate bone growth and regeneration. Demineralized
bone matrix can also combine with other materials e.g., cancellous
allograft, calcium sulfate to produce different form of composite
products. Jeffrey et al4 reported the use of DBX® to ﬁll up the bone
void after curettage of an enchondroma. Radiographs showed good
incorporation at 5 months after operation. In our series, the three
patients who received DBX® had radiographic incorporation at an
average of 21 weeks (range, 12e33 weeks). These results are
comparable to the 6-month remodelling time as suggested by the
manufacturer manual by Synthes.
Calcium phosphate bone cement is another artiﬁcial bone sub-
stitute used to treat enchondroma after curettage. Because it is in
the form of a paste, it can ﬁll up a bone void without any dead
space. However, care must be taken not to let the bone cement leak
out of the cavity, which may irritate the soft tissue and cause
complications. A commercial form is Norian SRS (Synthes). It con-
sists mainly of monocalcium phosphate and has high initial
strength for early mobilization. It was used in one of our patients.
Yasuda et al5 reported the usage of Biopex (Mitsubishi Materials
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treat enchondroma after curettage. Biopex mainly consists of tri-
calcium phosphate. It is prepared by mixing sterile white powder
with a sterile solution until a doughy form was obtained. It was
then injected as a paste form into the tumour cavity. Incorporation
occurred at an average of 4.5 months after surgery, whereas the
incorporation time was 12 weeks for our patient.
Choy et al6 used calcium sulfate pellet (Osteoset,WrightMedical
Co., Memphis, TN, USA) in the treatment of enchondroma after
curettage. Calcium sulfate serves as a scaffold for osteogenic cells
and neovascularization for generating new bone. The grafted cal-
cium sulfate acts as a space ﬁller preventing invasion of other soft
tissues. It is then gradually resorbed by subsequent bone remod-
elling. In their study, the calcium sulfate pellets were completely
resorbed by postoperative 6 weeks, followed by bone remodelling
at an average of postoperative 10 weeks. All patients achieved full
range of motion except one with pathological fracture, and no
recurrence or other complications were encountered.
Other substances have been used to ﬁll the bone defects after
curettage, including Plaster of Paris and hydroxyapatite. The use of
Plaster of Paris was ﬁrst described by Dreesman9 in 1892. The
plaster was reabsorbed after a few weeks and replaced by bone.
However, it came with the risk of reactions occurring during the
contact with soft tissue and development of ﬁstulas.10 It is no longer
a popular choice. Hydroxyapatite application has also been
described in the literature.11 However, some patients complained of
residual local pain, and this was attributed to the irritation by the
material at the soft tissue.
In our hospital, enchondromas presenting with pathological
fracture are all allowed to heal with splintage before deﬁnitive
curettage and bone grafting are performed. This is the common
school of thought in the literature, as concurrent intervention to the
fracture and the enchondromawill increase the complication rate.8
However, this has the disadvantage of delaying the histological
diagnosis and prolonging the disease process.1 With the develop-
ment of injectable calcium sulfate with high initial strength, Lin
et al12 reported the result of one-stage surgical treatment for
enchondromas presenting with pathological fracture in 2013. They
treated eight solitary enchondroma of a digit with undisplaced or
minimally displaced pathological fracture. All fractures healed after
a mean of 8 weeks after operation. The calcium sulfate cement was
completely absorbed and replaced by newly formed bone at 12
weeks after operation. Although further studies are needed to
determine whether injectable calcium sulfate can be applied in
treating displaced and unstable pathological fractures, it shows that
the development of newer and stronger artiﬁcial bone substitutes
could potentially shift our treatment paradigm.
In summary, the application of artiﬁcial bone substitutes in the
treatment of enchondroma is a sound alternative to iliac crestautograft. Artiﬁcial bone substitutes yield good functional and
radiographic outcome. Moreover, they can eliminate donor site
morbidities, decrease operation time, and hospital stay. They are
readily available and easy to use. Although artiﬁcial bone sub-
stitutes take a longer time to incorporate than iliac crest autograft
radiographically, it does not affect the functional outcome or union
rate.
This study is a small case series that concluded artiﬁcial bone
substitutes are good alternatives to iliac crest autograft in treating
hand enchondroma. Although we did not directly compare the
results between different artiﬁcial bone substitutes, we found that
DBX® putty was technically easy to apply and had good osteoin-
ductive properties. A larger patient group and longer term follow-
up for the efﬁcacy and comparison between different artiﬁcial
bone substitutes is needed.
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